Blood cancer registry study for biomarker discovery
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study collects samples and health information from people with certain blood cancers to learn more about the disease and find markers that may help guide future treatments. You will not receive a treatment from this study, but you may help advance research.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be willing to provide blood or tissue samples for research
- Be able to give your permission (informed consent) to participate
- You must have either acute myeloid leukemia (AML) or a type of follicular lymphoma (a slow-growing blood cancer)
- For AML: you must not have received any standard treatment yet
- For follicular lymphoma: your specific subtype determines whether you can be on active monitoring, need first treatment, have had early relapse, or have transformed disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study enrolls adults with certain blood cancers to better understand diagnosis, treatment choices, and outcomes. You may also be asked to provide or have tissue/blood samples saved so researchers can study what’s going on in the disease.
This trial studies how different blood cancers and early (pre-cancer) blood conditions work, using tumor/blood tissue samples. It may help researchers learn more about disease biology for future treatments, with little to no extra risk if samples come from routine care.
This study follows people who are newly diagnosed (and haven’t been fully treated yet) with specific leukemia or related blood disorders to help researchers learn which treatments may work best. It may help by connecting you to a larger “precision medicine” patient group for future research.
This study collects blood and tumor tissue samples from people newly diagnosed with aggressive non-Hodgkin lymphoma who will receive standard chemotherapy. The goal is to improve future tests for detecting minimal residual disease (tiny amounts of cancer left after treatment).
This study enrolls adults with acute myeloid leukemia (AML) to build a detailed registry and store biological samples. It helps researchers understand AML better and may support future studies.
This study looks at what leads to specific blood cancers and related blood disorders. If you have one of the listed conditions (or are being evaluated for it), you may be asked to join research that helps doctors understand why these illnesses happen.
Hear when a new Acute Myeloid Leukaemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.